Paravertebral anesthesia: How substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence

Breast Cancer Research and Treatment

Volumn 122, Issue 2, 2010, Pages 601-603

  Muñoz, Miguel ^a   Rosso, Marisa ^a   Casinello, Fernando ^b   Coveñas, Rafael ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; MORPHINE; NEUROKININ 1 RECEPTOR; SUBSTANCE P;

BREAST CANCER; BREAST CARCINOMA; CANCER INVASION; CANCER RECURRENCE; CELLULAR IMMUNITY; DRUG RECEPTOR BINDING; GENERAL ANESTHESIA; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; LETTER; MASTECTOMY; PATIENT CONTROLLED ANALGESIA; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGIONAL ANESTHESIA; SPINAL ANESTHESIA; SURGICAL STRESS; BREAST NEOPLASMS; FEMALE; METABOLISM; NEOPLASM RECURRENCE, LOCAL; SECONDARY; TREATMENT OUTCOME;

ANESTHESIA, SPINAL; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, NEUROKININ-1; SUBSTANCE P; TREATMENT OUTCOME;

EID: 77955653145     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0850-y     Document Type: Letter

References (17)

1. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI (2006) Can anesthetics technique for primary breast cancer surgery affect recurrence of metastases? Anesthesiology 105:660-664.
2. Kehlet H (1998) Modification of responses to surgery by neural blockade: clinical implications. In: Cousins M, Bridenbough M (eds) Neural blockade in clinical anesthesia and pain management. Lippincott-Raven, Philadelphia, pp 129-175.
3. Ben-Eliyahu S (2002) The price of anticancer intervention. Does surgery promote metastasis? Lancet Oncol 3:578-579.
4. Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, Ammatuna M, Panerai AE (2000) The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 90:1411-1414.
5. Yeager MP, Collacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J, Guyre PM (1995) Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 83:500-508.
6. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP (2002) Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signalling and promotes breast tumor growth. Cancer Res 62:4491-4498.
7. Muñoz M, Rosso M, Coveñas R (2010) A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 17:504-513.
8. Li YM, Wingrov DE, Too HP, Marnerakis M, Stimson ER, Strichartz GR, Maggio JE (1995) Local anesthetics inhibit substance P binding and evoked increases in intracellular Ca2?. Anesthesiology 82:166-173.
9. Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112:231-238.
10. Muñoz M, Rosso M, Aguilar FJ, González-Moles MA, Redondo M, Esteban F (2007) NK-1 receptor antagonists induce apoptosis and counteract substance p-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 26:111-118.
11. Khare VK, Albino AP, Reed JA (1998) The neuropeptide/mast cell secretagogue substance P is expressed in cutaneus melanocytic lesions. J Cutan Pathol 25:2-10.
12. Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance- P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786-792.
13. Singh D, Joshi DD, Hameed M, Qian J, Gascón P, Maloof PB, Mosenthal A, Rameshwar P (2000) Increased expression of preprotachykinin- I and neurokinin receptors in human breast cancer cells: Implications for bone marrow metastasis. Proc Natl Acad Sci USA 97:1388-1393.
14. Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ (2007) Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732, 138. Invest Ophthalmol Vis Sci 48:2775-2781.
15. Guha S, Eibl G, Kisfalvi K, Fan RS, Burdick M, Reber H, Hines OJ, Strieter R, Rozengurt E (2005) Broad-spectrum G proteincoupled receptor antagonist, [D-Arg1, DTrp5, 7, 9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 65:2738-2745.
16. Meshki J, Douglas SD, Lai JP, Schwartz L, Kilpatrick LE, Tuluc F (2009) Neurokinin 1-receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinasedependent mechanism. J Biol Chem 284:9280-9289.
17. Muñoz M, Rosso M (2009) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28:187-193.